Amarantus to announce results from preclinical study of new protein therapy for TBI

Jun 2 2012

Rainbow BioSciences, the biotech subsidiary of Rainbow Coral Corp. (OTCBB:RBCC), announced today that its latest joint venture target, Amarantus BioSciences, Inc. (OTCBB: AMBS), expects to announce the results of a preclinical study evaluating the potential of its new protein therapy as a treatment for Traumatic Brain Injury (TBI).

The study, commissioned late last year, is a collaboration between Amarantus and Banyan Biomarkers, the leader in developing in vitro diagnostic products to detect TBI. The effects of TBI can be debilitating to athletes, combat veterans and others at risk of repetitive or serious head trauma. The recent death of NFL great Junior Seau, widely believed to be related to TBI, has focused a great deal of attention on the need for an effective treatment.

RBCC believes that Amarantus is close to developing that cure. The company expects the test results, scheduled to be announced next week, to show that Amarantus new protein therapy, MANF, effectively reduces cell death associated with TBI.

RBCC and Amarantus are currently wrapping up due diligence toward a potential joint venture agreement to develop and market MANF as a treatment for disorders associated with endoplasmic reticulum stress, including traumatic brain injury, Parkinson's disease, Alzheimer's disease and other afflictions.

Source: Rainbow BioSciences